Overviewing the Clinical use of the CARM Score in Alzheimer Disease Detection: James Galvin, MD
An explanatory video on NeurologyLive features Dr. James Galvin, MD, MPH, Chief Scientific Officer at Cognivue, discussing the clinical use of Cognivue Clarity® and the new Cognivue Amyloid Risk Measure (CARM)*, and how these tools can inform clinical decisions and guide appropriate next steps in patient staging.
Predicting Amyloid Positivity with CARM: Clinical Insights from James Galvin, MD, MPH
A NeurologyLive news article highlights findings from the Bio-Hermes study that led to the development of Cognivue’s new prediction metric, the Cognivue Amyloid Risk Measure (CARM).* In the piece, Dr. James Galvin, MD, MPH, Chief Scientific Officer at Cognivue, shares clinical insights on how CARM, together with the overall Cognivue Clarity® score, provides meaningful support in predicting amyloid positivity.
